Company Overview - Sudeep Pharma is a technology-driven manufacturer of excipients and specialty ingredients used in the pharmaceutical, food, and nutrition sectors, leveraging in-house technologies to enhance manufacturing efficiency [7][8] - The company has established a global presence in over 100 countries, with significant market penetration in the US, South America, Europe, the Middle East, Africa, and Asia-Pacific [8] - Sudeep Pharma is one of the largest producers of food-grade iron phosphate, with an annual manufacturing capacity of 72,246 metric tonnes as of June 30, 2025 [8] IPO Details - Sudeep Pharma has set a price band of Rs 563–593 per equity share for its initial public offering (IPO), which aims to raise Rs 895 crore, opening for subscription on November 21 and closing on November 25 [2][10] - The IPO consists of a fresh issue of Rs 95 crore and an offer for sale (OFS) of 1,34,90,726 shares by promoters, amounting to Rs 800 crore at the upper price band [10] - The allocation for the IPO includes a maximum of 50% for qualified institutional buyers (QIBs), 15% for non-institutional investors (NIIs), and 35% for retail individual investors [5][10] Use of Proceeds - The company plans to allocate Rs 75.8 crore from the fresh issue for capital expenditure to procure machinery for its production line at the Nandesari Facility 1 in Gujarat, with the remaining funds directed towards general corporate purposes [6][10] Market Sentiment - Sudeep Pharma's shares are currently commanding a 16% grey market premium (GMP), indicating a likely listing price of around Rs 688, which suggests an estimated gain of about Rs 95 per share over the upper issue price of Rs 593 [10] - Recent IPOs have positively influenced investor sentiment, with notable listing gains observed in other companies, contributing to a favorable outlook for Sudeep Pharma's upcoming IPO [10]
Sudeep Pharma IPO: GMP jumps 16% ahead of November 21 launch. Check tentative listing price
The Economic Times·2025-11-19 08:51